Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database

Hoisnard, Léa; Lebrun‐Vignes, Bénédicte; Maury, Sébastien; Mahévas, Matthieu; El Karoui, Khalil; Roy, Lydia; Zarour, Anissa; Michel, Marc; L. Cohen, José; Amiot, Aurélien; Claudepierre, Pascal; Wolkenstein, P.; Grimbert, Philippe; Sbidian, É.

doi:10.1038/s41598-022-10777-w

Public

Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database

Published in Scientific Reports • May 3, 2022

Authors:

Léa Hoisnard

Bénédicte Lebrun‐Vignes

Sébastien Maury

Abstract

Increasing number of Janus kinase (JAK) inhibitors have been approved for chronic haematopoietic neoplasms and inflammatory/autoimmune diseases. We aimed to assess safety of the first three approved JAK inhibitors: ruxolitinib, tofacitinib and baricitinib. In this retrospective observational study, ...

Subject

Ruxolitinib

Tofacitinib

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!